TEVA(US:TEVA) Globenewswire·2026-01-28 12:00Core Insights - Teva Pharmaceutical Industries Ltd. reported a revenue of $17.3 billion for FY 2025, marking a 4% increase YoY in U.S. dollars and 3% in local currency terms, driven by key innovative products [7][11] - The company achieved a significant milestone with its innovative brands, collectively generating approximately $1 billion in revenues during Q4 2025 for the first time [4][9] - Teva's "Pivot to Growth" strategy has been instrumental in driving three consecutive years of growth, with a focus on innovative medicines, generics, and biosimilars [4][6] Financial Performance - Q4 2025 revenues reached $4.7 billion, an 11% increase YoY in U.S. dollars and 9% in local currency terms [28] - FY 2025 GAAP diluted earnings per share (EPS) were $1.21, while non-GAAP diluted EPS stood at $2.93, reflecting strong operational performance [2][21] - Cash flow from operating activities for FY 2025 was $1,649 million, with free cash flow amounting to $2,396 million, indicating robust cash generation capabilities [25][26] Innovative Product Growth - Key innovative brands, including AUSTEDO, AJOVY, and UZEDY, contributed significantly to revenue growth, with AUSTEDO alone generating $725 million in Q4 2025, a 40% increase YoY [9][52] - AJOVY's revenues increased by 68% YoY to $105 million in Q4 2025, driven by expanded indications and volume growth [51] - UZEDY revenues reached $55 million in Q4 2025, reflecting a 28% increase YoY, showcasing Teva's commitment to advancing neuroscience [55] Cost Management and Operational Efficiency - Teva's gross profit for FY 2025 was $8.9 billion, an 11% increase from 2024, with a gross profit margin of 51.8% [13] - The company achieved $70 million in savings in 2025 as part of its transformation programs, with expectations to realize two-thirds of targeted savings by 2026 [10][17] - Operating income for FY 2025 was $2.2 billion, a significant turnaround from an operating loss in 2024, reflecting improved operational efficiency [17] Market Dynamics and Segment Performance - The U.S. segment generated $2.6 billion in Q4 2025, a 34% increase YoY, primarily due to innovative product growth and milestone payments [45] - The Europe segment reported revenues of $1.3 billion in Q4 2025, a 3% decrease YoY, impacted by lower sales of certain product rights and generic products [62] - The International Markets segment saw revenues decline by 20% YoY to $528 million, largely due to the divestment of the Japan business venture [75]